Ensign Peak Advisors
OCUL icon

Ensign Peak Advisors’s Ocular Therapeutix OCUL Stock Holding History

Ensign Peak Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29,050
Closed -$117K – 2341
2022
Q2 		$117K Hold
29,050
– – ﹤0.01% 1931
2022
Q1 		$144K Buy
29,050
+14,020
+93% +$77.7K ﹤0.01% 1959
2021
Q4 		$105K Buy
15,030
+9,030
+151% +$70.1K ﹤0.01% 2051
2021
Q3 		$60K Hold
6,000
– – ﹤0.01% 1825
2021
Q2 		$85K Sell
6,000
-53,711
-90% -$816K ﹤0.01% 1792
2021
Q1 		$979K Buy
59,711
+39,711
+199% +$765K ﹤0.01% 1433
2020
Q4 		$414K Buy
+20,000
New +$297K ﹤0.01% 1636

Other funds holding OCUL

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Ensign Peak Advisors's OCUL Position: Q3 2022 in Review

Ensign Peak Advisors sold out of Ocular Therapeutix (OCUL) in Q3 2022, closing a stake of 29,050 shares — an estimated $117K sold.

Ensign Peak Advisors first reported a position in OCUL in Q4 2020 and held it in 7 quarters. The position peaked at $979K in Q1 2021. 130 funds tracked by Wall St. Rank hold OCUL as of Q3 2022.

  • Ensign Peak Advisors reported no remaining Ocular Therapeutix position as of Q3 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 29,050 Ocular Therapeutix shares in Q3 2022, an estimated $117K.
  • Ensign Peak Advisors first reported a position in Ocular Therapeutix in Q4 2020 and held it in 7 quarters.
  • Ensign Peak Advisors's Ocular Therapeutix position peaked at $979K in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2022.

Based on Ensign Peak Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.